LOBEF Stock Chart & Stats
$0.06
<$0.01(4.00%)
At close: 4:00 PM EDT
$0.06
<$0.01(4.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume1.56K
Average Volume (3M)69.68K
Market Cap
$17.87M
Enterprise Value$25.61
Total Cash (Recent Filing)$5.21M
Total Debt (Recent Filing)$338.40K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding308,182,160
10 Day Avg. Volume34,579
30 Day Avg. Volume69,684
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StabilizationThe return to positive equity provides a stronger capital base than in prior years and may improve financial resilience. However, declining assets and ongoing losses mean this stabilization remains incomplete.
Pipeline FinancingThe financing supplies resources for ongoing operations and development, reducing immediate funding pressure. It supports execution of the pipeline over the next several months, although it does not create recurring revenue.
S-100 Clinical DevelopmentProgress toward human trials could create a meaningful development milestone and improve the program’s partnering or commercialization potential. The benefit remains dependent on successful clinical execution and future funding.
Bears Say
No Current Revenue BaseThe absence of revenue indicates that the company lacks an established commercial engine and remains dependent on future pipeline success. This weakens operating visibility and makes progress toward sustainable self-funded growth uncertain.
Persistent Losses And Cash BurnContinued losses and negative free cash flow show that operations are not self-funding. Ongoing cash consumption increases reliance on additional financing and could constrain research, clinical development, or other strategic priorities.
Limited Financial FlexibilityHigher leverage relative to the reduced equity base and declining assets indicate a less flexible balance sheet. Combined with volatile earnings and ongoing losses, this may make future capital raising more important and potentially more difficult.
Lobe Sciences News
LOBEF FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was $0.02 and its highest was $0.11 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is $17.87M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Dec 18, 2026 which is in 101 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Jul 30, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 308,182,160 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went up 18.644%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in LOBEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―